Colorectal Cancer
Conditions
Keywords
colon cancer, Cancers of the colon and rectum, Oxaliplatin, oxaliplatin chemotherapy, inflammatory cytokines, neurocognitive symptoms, neuropsychiatric symptoms
Brief summary
The goal of this research study is to learn more about the pain and/or other symptoms that patients may experience within five years from CRC diagnosis. Researchers also want to learn how genetic differences may affect the symptoms patients experience from cancer and cancer therapy.
Detailed description
If you agree to take part in this study, you will complete 5 questionnaires during a regularly scheduled visit. The questionnaires are designed to measure pain and other symptoms, your mood, and your quality of life. You will also give a tissue sample by inserting a cotton tipped swab into your mouth and rubbing firmly against the inside of your cheek or underneath your lower or upper lip for about 1 minute at the most. Completing the 5 questionnaires and the swab sample should take about 30 minutes. Length of Study: After you complete the questionnaires and the swab sample collection, your active participation in this study will be over. This is an investigational study. Up to 500 patients will take part in this study. All will be enrolled at MD Anderson.
Interventions
BEHAVIORALQuestionnaires
20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
Sponsors
AstraZeneca
M.D. Anderson Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients with colorectal cancer meeting one of the following criteria: 1. naive to oxaliplatin or to any microtubule stabilizing agents (e.g. Taxol, Abraxane, Ixabepilone) but scheduled for combined oxaliplatine chemotherapy (longitudinal study cohort 1); or 2. during first 5 years from colorectal cancer diagnosis (cross-sectional study cohort). This second cohort may include patients with colorectal cancer from the original 12-month study (the longitudinal cohort), both those who completed the study and those who dropped out. It may also include new patients who did not participate in the longitudinal phase of the study. 2. Patients \>= 18 years old. 3. Patients who speak English or Spanish.
Exclusion criteria
1. Cohort 1 patients with a neuropathy score of 1 or greater on the NCI's Common Terminology Criteria (CTCv3.0). 2. Patients who do not understand the intent of the study. 3. Cohort 1 patients unable to use the interactive voice response (IVR) system due to physical limitations (e.g., hearing impairment). 4. Cohort 1 patients with a history of inflammatory bowel disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between inflammatory cytokines and development of treatment-related symptom burden in colorectal cancer patients | 5 Years |
Secondary
| Measure | Time frame |
|---|---|
| Primary afferent function in colorectal cancer patients receiving chemotherapy by quantitative sensory testing over time | 5 Years |
| Neurocognitive and neuropsychiatric symptoms in colorectal cancer patients | Neuropsychological test battery at baseline and 3 + 6 month follow ups |
Countries
United States
Outcome results
None listed